AndreaWang-GillamMD

Oncology • Saint Louis, MO

Gastrointestinal Cancer, Hematologic Oncology

Associate Professor, Internal Medicine, Washington University School of Medicine

Join to view full profile

Dr. Wang-Gillam is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Wang-Gillam's full profile

Already have an account?

Office
4921 Parkview Pl
# Dv
Saint Louis, MO 63110
Phone+1 800-647-2098

Fax+1 314-362-3192

Education & Training

University of Arkansas for Medical SciencesFellowship, Hematology and Medical Oncology, 2004 - 2007
University of Arkansas for Medical Sciences (UAMS) College of MedicineResidency, Internal Medicine, 2002 - 2004
Cleveland Clinic FoundationInternship, Internal Medicine, 2001 - 2002
University of Arkansas For Medical Sciences College of MedicineClass of 2001

Certifications & Licensure

MO State Medical License 2007 - 2026
AR State Medical License 2003 - 2009
OH State Medical License 2001 - 2003

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification Allscripts Enterprise EHR, Allscripts, 2012

Clinical Trials

Biweekly Intraperitoneal Oxaliplatin With Systemic Capecitabine and Bevacizumab for Patients With Peritoneal Carcinomatosis From Appendiceal or Colorectal Cancer Start of enrollment: 2011 May 10
Active, not recruiting
Phase 1
Registry Study - Whipple at the Splenic Artery Start of enrollment: 2010 Sep 20
Completed
FOLFIRINOX Plus PF-04136309 in Patients With Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma Start of enrollment: 2012 Apr 01
Completed
Phase 1
A Phase 1b/2 Study of OMP-59R5 (Tarextumab) in Combination With Nab-Paclitaxel and Gemcitabine in Subjects With Previously Untreated Stage IV Pancreatic Cancer Start of enrollment: 2012 Oct 01
Completed
Phase 1, Phase 2
Stereotactic Body Radiotherapy for Hepatocellular Carcinoma, and Intrahepatic Cholangiocarcinoma Start of enrollment: 2009 Dec 16
Completed
Phase 1
Combining MLN8237 With Nab-Paclitaxel in Patients With Advanced Solid Malignancies Start of enrollment: 2013 May 07
Completed
Phase 1
Levocetirizine + Capecitabine + Bevacizumab for Patients With Refractory Colorectal Cancer Start of enrollment: 2013 Apr 01
Completed
Phase 2
VEGFR/PDGFR Dual Kinase Inhibitor X-82 and Everolimus for Treating Patients With Pancreatic Neuroendocrine Tumors Start of enrollment: 2013 May 03
Terminated
Phase 1, Phase 2
PEGPH20 Plus Nab-Paclitaxel Plus Gemcitabine Compared With Nab-Paclitaxel Plus Gemcitabine in Participants With Stage IV Untreated Pancreatic Cancer Start of enrollment: 2013 May 14
Completed
Phase 2
Safety Study of Intratumoral Injection of Clostridium Novyi-NT Spores to Treat Patients With Solid Tumors That Have Not Responded to Standard Therapies Start of enrollment: 2013 Oct 01
Completed
Phase 1
Combination Chemotherapy in Treating Patients With Advanced Stomach, Gastroesophageal, or Esophageal Cancer Start of enrollment: 2013 Nov 08
Completed
Phase 2
Safety and Efficacy of Combination Listeria/GVAX Pancreas Vaccine in the Pancreatic Cancer Setting Start of enrollment: 2014 Feb 05
Completed
Phase 2
Gene Expression and FDG PET/MRI in Evaluating Treatment Response in Patients With Locally Advanced Rectal Cancer Undergoing Chemotherapy and Radiation Therapy Before Surgery Start of enrollment: 2014 Jun 01
Terminated
Phase 1
Vorolanib (X-82) Combined With Checkpoint Inhibitors in Patients With Solid Tumors Start of enrollment: 2018 Sep 11
Terminated
Phase 1
Liposomal Irinotecan Plus 5-FU / LV Combined With Paricalcitol in Patients With Advanced Pancreatic Cancer Progressed on Gemcitabine-based Therapy Start of enrollment: 2019 Jul 11
Completed
Phase 1
Join now to see all

Publications & Presentations

PubMed

1 citations
Neoantigen DNA vaccines are safe, feasible, and induce neoantigen-specific immune responses in triple-negative breast cancer patients.
Xiuli Zhang, S Peter Goedegebuure, Michael Y Chen, Rashmi Mishra, Felicia Zhang
Genome Medicine. 2024-11-14
11 citations
Defining the KRAS- and ERK-dependent transcriptome in KRAS-mutant cancers.
Jeffrey A Klomp, Jennifer E Klomp, Clint A Stalnecker, Kirsten L Bryant, A Cole Edwards
Science. 2024-06-07
2 citations
Intratumoral Cell Neighborhoods Coordinate Outcomes in Pancreatic Ductal Adenocarcinoma.
Max M Wattenberg, Sarah Colby, Ignacio Garrido-Laguna, Yuqing Xue, Renee Chang
Gastroenterology. 2024-06-01

Journal Articles

Efficacy of Perioperative Chemotherapy for Resectable Pancreatic Adenocarcinoma
Andrea Wang-Gillam, Howard S Hochster, JAMA Oncology
FOLFIRINOX for the Treatment of Advanced Gastroesophageal Cancers
Haeseong Park, Andrea Wang-Gillam, Caron Rigden, Katrina S Pedersen, Nikolaos A Trikalinos, JAMA Oncology

Lectures

Phase I study of defactinib combined with pembrolizumab and gemcitabine in patients with advanced cancer.
2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018

Authored Content

FOLFIRINOX for the Treatment of Advanced Gastroesophageal CancersMay 2020

Press Mentions

Verastem Oncology Reports Second Quarter 2018 Financial ResultsAugust 8th, 2018
Verastem Oncology Presents Data on Two Lead Drug Candidates at ASCO 2018 Annual MeetingJune 4th, 2018
Defactinib Combined with Pembrolizumab and Gemcitabine in Patients with Advanced CancerApril 18th, 2016
Join now to see all